Prostate Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Prostate Cancer stocks.

Prostate Cancer Stocks Recent News

Date Stock Title
May 15 LNTH Lantheus Announces Executive Appointments to Accelerate Innovation
May 15 INO Inovio Pharmaceuticals, Inc. (INO) Presents at 2024 RBC Capital Markets Global Healthcare Conference (Transcript)
May 15 EDAP EDAP TMS S.A. Q1 2024 Earnings Preview
May 15 IONS Ionis to host 2024 virtual Annual Meeting of Stockholders
May 14 INO Inovio Pharmaceuticals, Inc. (INO) The Citizens JMP Life Sciences Conference (Transcript)
May 14 EPIX ESSA Pharma GAAP EPS of -$0.20 misses by $0.01
May 14 EPIX ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024
May 14 INO Inovio Pharmaceuticals Inc (INO) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
May 14 INO Inovio Pharmaceuticals (INO) Q1 2024 Earnings Call Transcript
May 13 INO Inovio Pharmaceuticals, Inc. (INO) Q1 2024 Earnings Call Transcript
May 13 INO Inovio Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation
May 13 INO Inovio Pharmaceuticals GAAP EPS of -$1.31 misses by $0.31
May 13 INO INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 13 JAZZ Avadel gains for a second day as analysts see it prevailing in case vs Jazz/FDA
May 12 INO Inovio Pharmaceuticals Q1 2024 Earnings Preview
May 12 EXEL Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
May 11 EXEL Exelixis files patent suit against India’s Cipla over Cabometyx generics
May 11 MYGN Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report
May 10 JAZZ Avadel Pharma gains during hearing over dispute on FDA approval of a sleep disorder drug (update)
May 10 EDAP EDAP TMS S.A.'s (NASDAQ:EDAP) top owners are individual investors with 56% stake, while 24% is held by institutions
Prostate Cancer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.Factors that increase the risk of prostate cancer include older age, a family history of the disease, and race. About 99% of cases occur in males over the age of 50. Having a first-degree relative with the disease increases the risk two to threefold. In the United States, it is more common in the African American population than the White American population. Other factors that may be involved include a diet high in processed meat, red meat or milk products or low in certain vegetables. An association with gonorrhea has been found, but a reason for this relationship has not been identified. An increased risk is associated with the BRCA mutations. Prostate cancer is diagnosed by biopsy. Medical imaging may then be done to determine if the cancer has spread to other parts of the body.Prostate cancer screening is controversial. Prostate-specific antigen (PSA) testing increases cancer detection, but it is controversial regarding whether it improves outcomes. Informed decision making is recommended when it comes to screening among those 55 to 69 years old. Testing, if carried out, is more reasonable in those with a longer life expectancy. While 5α-reductase inhibitors appear to decrease low-grade cancer risk, they do not affect high-grade cancer risk and thus are not recommended for prevention. Supplementation with vitamins or minerals does not appear to affect the risk.Many cases are managed with active surveillance or watchful waiting. Other treatments may include a combination of surgery, radiation therapy, hormone therapy or chemotherapy. When it only occurs inside the prostate, it may be curable. In those in whom the disease has spread to the bones, pain medications, bisphosphonates and targeted therapy, among others, may be useful. Outcomes depend on a person's age and other health problems as well as how aggressive and extensive the cancer is. Most men with prostate cancer do not end up dying from the disease. The 5-year survival rate in the United States is 99%. Globally, it is the second most common type of cancer and the fifth leading cause of cancer-related death in men. In 2012, it occurred in 1.1 million men and caused 307,000 deaths. It was the most common cancer in males in 84 countries, occurring more commonly in the developed world. Rates have been increasing in the developing world. Detection increased significantly in the 1980s and 1990s in many areas due to increased PSA testing. Studies of males who died from unrelated causes have found prostate cancer in 30% to 70% of those over age 60.

Browse All Tags